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insulinomas and nonfunctioning pancreatic NEN, and de-
creased in ileal and bronchopulmonary NEN with increasing 
MIB-1 rate. MIB-1 levels were identified, above which GIP re-
ceptor levels were consistently high or low. These MIB-1 lev-
els were clearly different from those defining tumor grade. 
In grade 3 NEN, GIP receptor levels were always low, while 
sst2 levels were variable and sometimes extremely high. 
Conversely, sst2 expression correlated more frequently with 
tumor stage than GIP receptor expression, with metasta-
sized NEN showing higher sst2 levels than localized tumors. 
 Conclusions: sst2, a clinically crucial molecular target, shows 
variable and unpredictable expression in NEN irrespective of 
tumor grade. Therefore, each NEN should be tested for sst2 
if clinical applications with somatostatin analogs are consid-
ered. Conversely, the potential future role of GIP receptors 
as molecular targets in NEN may be dependent on the MIB-1 
level.  © 2015 S. Karger AG, Basel 
 Introduction 
 Gut and extraintestinal neuroendocrine neoplasms 
(NEN) represent challenging tumors in terms of clinical 
management and research due to various features such as 
 Key Words 
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 Abstract 
 Background/Aims: Important characteristics of neuroendo-
crine neoplasms (NEN) for prognosis and therapeutic deci-
sions are the MIB-1 proliferative index (tumor grade) and tu-
mor stage. Moreover, these tumors express peptide hor-
mone receptors like somatostatin and gastric inhibitory 
peptide (GIP) receptors which represent important estab-
lished and potential future targets, respectively, for molecu-
lar imaging and radiotherapy. However, the interrelation
between tumor proliferation, stage, and peptide receptor 
amounts has never been assessed.  Methods: In 114 gastro-
intestinal and bronchopulmonary NEN, the proliferative rate 
assessed with MIB-1 immunohistochemistry and tumor 
stage were compared with the somatostatin type 2 receptor 
(sst2) and GIP receptor expression measured quantitatively 
with in vitro receptor autoradiography.  Results: NEN gener-
ally showed high sst2 and GIP receptor expression. GIP re-
ceptor but not sst2 expression correlated with the MIB-1 in-
dex. GIP receptor levels gradually increased in a subset of 
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rarity, heterogeneity with respect to site of origin and hor-
mone production, slow growth and progression, and 
metastatic potential. However, biological characteriza-
tion of individual tumors is significantly improved by de-
termining specific prognostic and predictive markers.
 Important prognostic factors for NEN are tumor grade 
and stage. The grade is based on the proliferative activity 
of the tumor assessed by the mitotic rate or by Ki-67 im-
munohistochemistry. The stage reflects tumor size, inva-
siveness, and presence of nodal and distant metastasis, 
and is described in the TNM classification. Both grade 
and stage correlate well with prognosis  [1–3] . They are 
essential criteria for a standardized patient management 
 [4, 5] as well as represent a basis for the comparability of 
clinical studies. Therefore, various comparable consensus 
guidelines for the grading and staging of NEN were de-
veloped in the last years, such as those by the ENETS, 
NANETS, WHO, and AJCC  [6–10] , and have been wide-
ly adopted since. 
 Lately, particular attention has been paid to the prolif-
erative index assessed by Ki-67 immunohistochemistry as 
a marker of tumor biology and prognosis. Indeed, the Ki-
67 index has been shown to strongly correlate with sur-
vival  [3, 11] . However, its value is limited due to inter-
laboratory and interobserver variability in the Ki-67 as-
sessment  [12] and a potential sampling bias in small 
biopsy specimens. Likewise, the significance of tumor 
grade may be limited since tumor grade is defined by ar-
bitrary Ki-67 cutoff values used for tumor grading  [13] , 
and grade 2 tumors comprise a large spectrum of Ki-67 
positivity rate, ranging from 2 to 20%. 
 NEN are also characterized by the high expression of 
peptide hormone receptors. These are markers predictive 
of the suitability of an individual tumor for an in vivo tar-
geting with radiolabeled peptide analogs for imaging and 
therapeutic purposes  [14] . Of importance, the success of 
peptide receptor targeting of NEN strongly correlates 
with the amount of tumoral peptide receptors. Clinically 
best established is targeting of somatostatin receptors, 
which are typically expressed at high levels and in high 
incidence in NEN  [15, 16] . A promising new candidate 
for such a NEN targeting with radioactive compounds is 
the gastric inhibitory peptide (GIP) receptor which was 
only recently found to be universally overexpressed in gut 
and lung NEN  [17] . In vivo GIP receptor targeting of tu-
mors was successful in animals in xenografted tumors ex-
pressing GIP receptors  [18] , but has not yet been tested 
in human patients. 
 Although it is known that somatostatin and GIP re-
ceptors are widely expressed in gut and lung NEN, a sys-
tematic correlation between quantitative levels of these 
predictive markers and the proliferative index as a bio-
logical and prognostic marker has, to our knowledge, 
not yet been performed. At present, it is generally as-
sumed that high-grade tumors are not suitable for soma-
tostatin receptor targeting because of a low somatostatin 
receptor incidence and density  [5, 19] . Somatostatin re-
ceptor imaging is, therefore, recommended only for 
grade 1 and 2 tumors, but considered optional for grade 
3 tumors  [20] . However, published objective data to 
support a generally low somatostatin receptor expres-
sion in tumors with high proliferative rates are scarce. 
Likewise, it is unknown if somatostatin and GIP recep-
tor expression levels also correlate with proliferation in 
grade 1 and 2 tumors or with metastatic behavior. There-
fore, the aim of the present study was to compare soma-
tostatin and GIP receptor levels measured quantitative-
ly by in vitro receptor autoradiography in resected tu-
mor specimens with the immunohistochemical prolif-
erative index and tumor stage in common gut and lung 
NEN. Since NEN represent an anatomically and biolog-
ically heterogeneous tumor group, NEN of different 
sites of origin and with different hormone production 
were analyzed separately.
 Materials and Methods 
 Tumors 
 A total of 114 NEN of gastroenteropancreatic and bronchopul-
monary origin were investigated. These included 20 ileal NEN, 17 
nonfunctioning pancreatic NEN, 53 functioning pancreatic NEN 
(40 insulinomas, 5 gastrinomas, 3 glucagonomas, 5 VIPomas), 1 
duodenal gastrinoma, and 23 bronchopulmonary carcinoids. All 
tumors were primaries except for 5 cases, which included liver me-
tastases of an ileal NEN, a nonfunctioning pancreatic NEN and a 
VIPoma, as well as lymph node metastases of an insulinoma and a 
bronchopulmonary carcinoid. The majority of the tumors had 
been analyzed previously for peptide receptors  [17, 21–24] . In par-
ticular, GIP receptor expression of most cases has been published 
previously  [17] , except for 4 cases. The remaining tumors had been 
collected newly at the Institute of Pathology of the University of 
Bern. Informed consent was obtained from all patients. The study 
collection conformed to the ethical guidelines of and was reviewed 
by the Institutional Review Board. 
 Tumor grade of the gastroenteropancreatic NEN was deter-
mined using MIB-1 immunohistochemistry according to Rindi et 
al. [6, 25] (grade 1: MIB-1  ≤ 2%; grade 2: MIB-1 >2–20%; grade 3: 
MIB-1 >20%). Bronchopulmonary carcinoid tumors were graded 
similarly, although the immunohistochemical proliferative index 
is not yet established for grading NEN at this site  [26] . Where avail-
able, the TNM stage was retrieved from the patient records. Tu-
mors were divided into those without evidence of metastasis (N0 
M0) and those with nodal and/or distant metastases (N+ and/or 
M+). 
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 In vitro Somatostatin Receptor and GIP Receptor 
Autoradiography  
 In vitro autoradiography for somatostatin and GIP receptors 
was carried out as described previously  [17, 27] . Briefly, 20-μm-
thick cryostat sections of tumor tissues were incubated with either 
 125 I-[Tyr3]-octreotide (Anawa, Wangen, Switzerland) (for soma-
tostatin receptors) or  125 I-GIP(1–30) (Anawa) (for GIP receptors) 
for 2 h at room temperature. Nonspecific binding was assessed by 
incubating serial tissue sections with the radioligand in the pres-
ence of excess cold peptide. Then, the slides were exposed to Kodak 
films Biomax MR ® for 7 days at 4   °   C. Radioligand binding to the 
tumors was analyzed in correlation with morphology using cor-
responding hematoxylin and eosin-stained tissue sections. Radio-
ligand binding densities were measured in dpm/mg tissue using 
MIB-1 (%) MIB-1 (%)
125I-[Tyr3]-octreotide
binding density
125I-GIP(1–30)
binding density
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 Fig. 1. Relationship between the MIB-1 
proliferative index (%; x-axis) and  125 I-
[Tyr3]-octreotide and  125 I-GIP(1–30) 
binding density levels (dpm/mg tissue; y-
axis) in individual NEN. Above a cutoff 
value of 3,000 dpm/mg radioligand bind-
ing density, receptor levels were considered 
high. All ileal NEN with MIB-1  ≥ 16% as 
well as bronchial NEN with MIB-1  ≥ 8% 
show low or no GIP receptor expression. 
Conversely, all grade 2 nonfunctioning 
pancreatic NEN with MIB-1 >5% and >2% 
show high sst2 and GIP receptor levels, re-
spectively. Insulinomas with MIB-1 be-
tween 2 and 5% show either no or extreme-
ly high sst2 levels, but more variable GIP 
receptor levels. GI = Gastrointestinal. 
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sst2 receptors  GIP receptors
incidence density inc idence density
mean1 ± SEM low2 moderate2 high2 mean1 ± SEM low2 moderate2 high2
All gastrointestinal NEN
MIB-1 ≤2% 22/32 (69%) 7,352 ± 725 2 2 18 31/31 (100%) 3,583 ± 501 7 9 16
MIB-1 2 – 20% 37/52 (71%) 7,487 ± 534 2 4 31 51/51 (100%) 5,299 ± 442 3 10 38
MIB-1 >20% 4/7 (57%) 9,092 ± 908 0 0 4 3/7 (43%) 2,962 ± 984 1 0 2
All 63/91 (69%) 7,541 ± 406 4 6 53 86/90 (96%) 4,579 ± 335 11 19 56
N0 M0 9/25 (36%) 6,197 ± 1,346 2 1 6 24/24 (100%) 3,889 ± 586 2 9 13
N+ and/or M+ 33/39 (85%) 7,824 ± 518 1 3 29 37/39 (95%) 5,726 ± 521 3 3 31
Ileal NEN
MIB-1 ≤2% 5/5 (100%) 6,678 ± 1,560 0 1 4 5/5 (100%) 5,216 ± 1,437 1 0 4
MIB-1 2 – 20% 11/12 (92%) 6,171 ± 1,115 1 2 8 12/12 (100%) 5,714 ± 902 0 2 10
MIB-1 >20% 1/3 (33%) 10,000 0 0 1 0/3 (0%) 0 0 0
All 17/20 (85%) 6,545 ± 855 1 3 13 17/20 (85%) 5,567 ± 741 1 2 14
N0 M0 – –
N+ and/or M+ 13/15 (87%) 5,872 ± 996 1 3 9 13/15 (87%) 5,751 ± 682 1 2 10
Nonfunctioning pancreatic NEN
MIB-1 ≤2% 2/2 (100%) 9,024 ± 976 0 0 2 2/2 (100%) 2,849 ± 1,456 0 1 1
MIB-1 2 – 20% 12/14 (86%) 8,582 ± 529 0 0 12 13/13 (100%) 7,011 ± 732 0 0 13
MIB-1 >20% 0/1 (0%) 0 0 0 0/1 (0%) 0 0 0
All 14/17 (82%) 8,645 ± 464 0 0 14 15/16 (94%) 6,456 ± 749 0 1 14
N0 M0 3/4 (75%) 9,080 ± 920 0 0 3 3/3 (100%) 5,835 ± 2,107 0 0 3
N+ and/or M+ 10/11 (91%) 8,448 ± 603 0 0 10 11/11 (100%) 6,680 ± 900 0 1 10
Insulinomas
MIB-1 ≤2% 11/21 (52%) 6,390 ± 1,152 2 1 8 21/21 (100%) 2,570 ± 501 6 8 7
MIB-1 2 – 20% 7/17 (41%) 7,537 ± 1,607 1 1 5 17/17 (100%) 3,274 ± 653 3 7 7
MIB-1 >20% 2/2 (100%) 8,184 ± 1,816 0 0 2 2/2 (100%) 3,946 ± 89 0 0 2
All 20/40 (50%) 6,971 ± 843 3 2 15 40/40 (100%) 2,938 ± 383 9 15 16
N0 M0 5/20 (25%) 4,258 ± 2,007 2 1 2 20/20 (100%) 3,363 ± 571 2 9 9
N+ and/or M+ 3/4 (75%) 9,121 ± 879 0 0 3 4/4 (100%) 4,387 ± 1,497 1 0 3
Gastrinomas
MIB-1 ≤2% 3/3 (100%) 10,000 ± 0 0 0 3 3/3 (100%) 6,739 ± 1,006 0 0 3
MIB-1 2 – 20% 3/3 (100%) 9,080 ± 920 0 0 3 3/3 (100%) 7,360 ± 1,962 0 0 3
MIB-1 >20% – –
All 6/6 (100%) 9,540 ± 460 0 0 6 6/6 (100%) 7,050 ± 996 0 0 6
N0 M0 1/1 (100%) 7,239 0 0 1 1/1 (100%) 8,556 0 0 1
N+ and/or M+ 3/3 (100%) 10,000 ± 0 0 0 3 3/3 (100%) 6,237 ± 1,456 0 0 3
Glucagonomas
MIB-1 ≤2% 1/1 (100%) 10,000 0 0 1 1/1 (100%) 8,676 0 0 1
MIB-1 2 – 20% 1/2 (50%) 2,764 0 1 0 2/2 (100%) 3,318 ± 2,246 0 1 1
MIB-1 >20% – –
All 2/3 (67%) 6,382 ± 3,618 0 1 1 3/3 (100%) 5,104 ± 2,207 0 1 2
N0 M0 – –
N+ and/or M+ 1/2 (50%) 10,000 0 0 1 2/2 (100%) 7,120 ± 1,556 0 0 2
VIPomas
MIB-1 ≤2% – –
MIB-1 2 – 20% 3/4 (75%) 7,759 ± 2,205 0 0 3 4/4 (100%) 6,549 ± 1,353 0 0 4
MIB-1 >20% 1/1 (100%) 10,000 0 0 1 1/1 (100%) 994 1 0 0
All 4/5 (80%) 8,347 ± 1,654 0 0 4 5/5 (100%) 5,438 ± 1,527 1 0 4
N0 M0 – –
N+ and/or M+ 3/4 (75%) 10,000 ± 0 0 0 3 4/4 (100%) 4,708 ± 1,732 1 0 3
 Table 1.  sst2 and GIP receptor incidences and mean densities according to MIB-1 levels and tumor stage in different NEN subgroups
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tissue standards containing known amounts of isotope and cross-
calibrated to tissue-equivalent ligand concentrations  [28, 29] as 
well as a computer-assisted imaging system (Interfocus, Mering, 
Germany). Due to saturation of radioligand binding to receptor 
binding sites in the tissues, the maximum binding density value 
measurable with the method was 10,000 dpm/mg. Radioligand 
binding densities <1,000 dpm/mg tumor tissue were considered to 
correspond to low tumoral receptor levels, densities between 1,000 
and 3,000 dpm/mg to moderate receptor levels, and densities 
>3,000 dpm/mg to high receptor levels  [17] . In the case of soma-
tostatin receptors, density levels above 3,000 dpm/mg were expect-
ed to be high enough for positive somatostatin receptor imaging, 
based on previous comparative data  [24, 30, 31] .
 MIB-1 Immunohistochemistry  
 The immunohistochemical Ki-67 proliferative index of NEN 
was assessed using an MIB-1 antibody (Dako, Glostrup, Den-
mark). Frozen tissue sections of the same tumor samples subjected 
to in vitro receptor autoradiography were fixed in acetone and 
postfixed in 4% formalin. The primary antibody was applied at a 
1: 50 concentration. The secondary antibody was a biotinylated 
goat anti-mouse immunoglobulin (1: 300; Dako). Antibody bind-
ing was visualized using the ABComplex Elite (Vector Laborato-
ries, Burlingame, Calif., USA). Staining was carried out with 
3,3 ′ -diaminobenzidine, and counterstaining with hemalum. In 
each case, the percentage of MIB-1-positive tumor cells was as-
sessed by counting 2,000 tumor cells. 
 Statistical Evaluation  
 Linear regression analysis and the Spearman’s rank correlation 
coefficient r 2 were used to correlate the MIB-1 proliferative index 
with autoradiographic receptor density levels, and the p value was 
calculated using Student’s t test. Fisher’s exact test and Student’s t 
test were applied to compare receptor incidences and densities be-
tween N0 M0 and N+/M+ tumors. p  ≤ 0.05 was considered to be 
statistically significant. 
 Results 
 Proliferative Index and Somatostatin and GIP 
Receptor Expression in NEN  
 The MIB-1 proliferative index as well as the soma-
tostatin and GIP receptor density levels were assessed 
with immunohistochemistry and receptor autoradiog-
Table 1 (continued)
sst2 receptors  GIP receptors
incidence density inc idence density
mean1 ± SEM low2 moderate2 high2 mean1 ± SEM low2 moderate2 high2
Bronchopulmonary NEN
MIB-1 ≤2% 1/3 (33%) 6,686 0 0 1 2/3 (67%) 649 ± 243 2 0 0
MIB-1 2 – 20% 11/19 (58%) 7,168 ± 1,018 0 2 9 18/19 (95%) 3,517 ± 702 5 7 6
MIB-1 >20% 0/1 (0%) 1/1 (100%) 442 1 0 0
All 12/23 (52%) 7,128 ± 930 0 2 10 21/23 (91%) 3,097 ± 642 8 7 6
N0 M0 3/7 (43%) 6,936 ± 2,268 0 0 3 7/7 (100%) 4,056 ± 1,037 2 1 4
N+ and/or M+ 3/4 (75%) 8,452 ± 934 0 1 2 3/4 (75%) 742 ± 150 3 0 0
 1 Only receptor-positive cases. 2 Low receptor density: <1,000 dpm/mg; moderate receptor density: 1,000 – 3,000 dpm/mg; high 
receptor density: >3,000 dpm/mg.
 Table 2. Individual MIB-1 values and sst2 and GIP receptor density 
levels in high-grade NEN with MIB-1 >20% and metastases of 
NEN 
Tumor type MIB-1, 
%
Density, dpm/mg
sst2 GIP receptor
High-grade NEN
Ileal NEN 42 0 0
50 0 0
51 10,000 0
Nonfunctioning pancreatic NEN 24 0 0
Insulinoma 22 10,000 3,857
23 6,368 4,035
VIPoma 26 10,000 994
Bronchial NEN 23 0 442
NEN metastases
Ileal NEN (liver) 1 7,220 956
Nonfunctioning pancreatic 
NEN (liver) 16 9,306 5,854
Insulinoma (lymph node) 12 0 7,198
VIPoma (liver) 13 10,000 9,141
Bronchial NEN (lymph node) 6 0 2,300
Organ in parentheses indicates site of metastasis.
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raphy, respectively, in the same tumor specimen and 
were compared with each other. For somatostatin re-
ceptor autoradiography, the radioligand  125 I-[Tyr3]-
octreotide was used, which mainly recognizes the so-
matostatin receptor subtype 2 (sst2). The results are 
shown for each individual case in  figure 1 and are
summarized in  table 1 . In addition,  table 2 shows the 
individual results of all grade 3 tumors and of the me-
tastases. 
 Gastrointestinal NEN in General 
 Looking at all NEN of gastrointestinal origin, tumors 
with an MIB-1 proliferative index  ≤ 20% frequently 
showed a high expression of both sst2 and GIP receptors, 
with a lower incidence but higher mean density of the 
former. The incidences amounted to around 70% for sst2 
and reached 100% for GIP receptors. Moreover, both sst2 
and GIP receptors were expressed at high density levels 
(i.e. >3,000 dpm/mg tumor tissue, expected to be high 
125I-[Tyr3]-octreotide binding density MIB-1HE
Total Total NonspecificNonspecific
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enough for clinical applications) in over half of the tu-
mors with MIB-1 positivity <2% and 59 and 74%, respec-
tively, of cases with an MIB-1 proliferative index between 
2 and 20%. 
 In 7 gastrointestinal NEN, the MIB-1 proliferative in-
dex exceeded 20%. Compared with NEN with less prolif-
eration, these tumors generally showed lower receptor 
incidences (57% for sst2, 43% for GIP receptors). Re-
markably, receptor density levels were still high in a sub-
set of these tumors ( table 2 ). This was particularly the case 
for sst2, which was expressed at extremely high levels in 
all 4 sst2-positive tumors. Conversely, GIP receptor levels 
were markedly reduced with increasing proliferative 
rates. Specifically, in NEN with MIB-1 >23%, GIP recep-
tors were expressed at low levels (i.e. <1,000 dpm/mg tu-
mor tissue) or were completely absent. 
 Ileal NEN 
 Separate analyses of individual subgroups of gastroin-
testinal NEN were also performed. Ileal tumors were thus 
found to generally express both sst2 and GIP receptors in 
high incidence and high density. However, the GIP recep-
tor density levels progressively declined with increasing 
MIB-1 positivity, which was statistically significant (r 2 = 
0.276; p = 0.017). In particular, all tumors with an MIB-1 
positivity rate  ≥ 16% showed low densities of or were 
completely negative for GIP receptors. In contrast, 1 of 
the 4 ileal NEN with MIB-1  ≥ 16% still exhibited a very 
high sst2 density. 
 Two representative ileal NEN are depicted in  figure 2 . 
The tumor in the first row shows a low MIB-1 expression 
(3.4%) together with a strong specific binding of the
radioligands  125 I-[Tyr3]-octreotide and  125 I-GIP(1–30), 
corresponding to a high number of sst2 and GIP receptor 
binding sites, respectively. In contrast, the example in the 
second row is characterized by a high MIB-1 positivity 
rate of 24%, but no specific binding of  125 I-[Tyr3]-octreo-
tide or  125 I-GIP(1–30); there are no detectable sst2 or GIP 
receptors in this tumor.
 Nonfunctioning Pancreatic NEN  
 Also in nonfunctioning pancreatic NEN, tumors with 
an MIB-1 proliferative index  ≤ 20% showed high expres-
sion of both sst2 and GIP receptors, whereas a single case 
with MIB-1 >20% was completely receptor negative. Re-
ceptor density levels were extremely high, even higher 
than in ileal NEN. There was an insignificant trend for an 
increase in receptor density levels with increasing MIB-1. 
In fact, in tumors with an MIB-1 proliferative index  ≥ 2%, 
the GIP receptor density was always high. The same holds 
true for sst2 in tumors with MIB-1 >5%. This is illustrat-
ed in  figure 2 . In the example in the third row with an 
MIB-1 positivity rate of 4%, there are no detectable soma-
tostatin receptors and GIP receptor levels just above 3,000 
dpm/mg, while the tumor in the fourth row with an MIB-
1 positivity rate of 16% exhibits very high levels of both 
receptors. 
 Fig. 2. Comparison of  125 I-[Tyr3]-octreotide and  125 I-GIP(1–30) 
binding autoradiography with MIB-1 immunohistochemistry in 
two different ileal NEN (rows 1 and 2) and two nonfunctioning 
pancreatic NEN (rows 3 and 4). The first 5 images in each row 
show serial tissue sections of the same tumor specimen at the same 
scanning magnification (bars = 1 mm); the last image in the row 
shows MIB-1 immunohistochemistry in the same specimen at 
higher magnification (bars = 0.1 mm). Column 1: HE staining. 
Columns 2 and 3:  125 I-[Tyr3]-octreotide autoradiography, where 
column 2 shows total  125 I-[Tyr3]-octreotide binding and column 
3 nonspecific  125 I-[Tyr3]-octreotide binding in the presence of ex-
cess cold octreotide. Columns 4 and 5:  125 I-GIP(1–30) autoradiog-
raphy, where column 4 shows total  125 I-GIP(1–30) binding and 
column 5 nonspecific  125 I-GIP(1–30) binding in the presence of 
excess cold GIP(1–30). Column 6: MIB-1 immunohistochemistry. 
 a–f Ileal NEN with high sst2 and GIP receptor expression and low 
proliferation.  a HE staining showing the tumor tissue.  b Strong 
total  125 I-[Tyr3]-octreotide binding to the entire tumor sample.
 c Complete displacement of  125 I-[Tyr3]-octreotide by cold octreo-
tide provides evidence of specificity of  125 I-[Tyr3]-octreotide bind-
ing to sst2; no nonspecific  125 I-[Tyr3]-octreotide binding.  d Simi-
larly, strong total  125 I-GIP(1–30) binding to the entire tumor sam-
ple.  e Complete displacement of  125 I-GIP(1–30) by cold GIP 
proves specificity of  125 I-GIP(1–30) binding.  f 3.4% of tumor cells 
stain for MIB-1.  g–m Ileal NEN without sst2 or GIP receptor ex-
pression, with high proliferation.  g HE staining showing tumor 
tissue.  h ,  i No specific  125 I-[Tyr3]-octreotide binding to the tumor. 
 k ,  l No specific  125 I-GIP(1–30) binding to the tumor.  m 24% of tu-
mor cells are positive for MIB-1.  n–s Nonfunctioning pancreatic 
NEN without sst2 expression, with marginally elevated GIP recep-
tor levels and low proliferation.  n HE staining showing tumor tis-
sue.  o ,  p No specific  125 I-[Tyr3]-octreotide binding to the tumor. 
 q ,  r Weak specific  125 I-GIP(1–30) binding to the tumor.  s 4.1% of 
tumor cells are MIB-1 positive.  t–x Nonfunctioning pancreatic 
NEN with very high sst2 and GIP receptor expression and high 
proliferation.  t HE staining showing tumor tissue.  u ,  v Very strong 
specific binding of  125 I-[Tyr3]-octreotide.  w ,  x Very strong spe-
cific binding of  125 I-GIP(1–30), markedly stronger than in  q .  y 16% 
of tumor cells stain for MIB-1.  
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 Insulinomas 
 In general, insulinomas with an MIB-1 proliferative 
index <20% expressed sst2 at moderate incidence rates 
with very high mean densities, and GIP receptors at 100% 
incidence rates with moderate mean densities. Many in-
sulinomas exhibited a proliferative index between 2 and 
5%. In this subset of tumors, sst2 and GIP receptor ex-
pression patterns differed even more markedly. Most cas-
es were either very strongly positive or completely nega-
tive for sst2. In contrast, there was a continuous increase 
in GIP receptor density levels with increasing MIB-1 pos-
itivity rate. If one outlying case (GIP receptor density 
9,818 dpm/mg, MIB-1 2.5%) was excluded, this increase 
was even statistically significant (r 2 = 0.3663; p = 0.017). 
All insulinomas with MIB-1  ≥ 5% showed high GIP re-
ceptor levels, including 2 cases with MIB-1 >20%.
 Other Functioning Pancreatic and Duodenal NEN  
 Only a few cases of other functioning NEN, including 
gastrinomas, glucagonomas, and VIPomas, were avail-
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 Fig. 3. Comparison of binding site levels 
(dpm/mg tissue) of sst2 (x-axis) and GIP 
receptors (y-axis) in individual cases. Black 
points: cases with comparable sst2 and GIP 
receptor density levels; red points: cases 
with high sst2 but low GIP receptor density 
levels; blue points: cases with high GIP re-
ceptor but low sst2 density levels. Particu-
larly insulinomas often show disparate sst2 
and GIP receptor levels.  
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able for examination. All 6 gastrinomas were strongly 
positive for both sst2 and GIP receptors, irrespective of 
the MIB-1 proliferative index. Glucagonomas showed 
high sst2 and GIP receptor densities in the case of MIB-1 
<2%, but lower receptor levels when the MIB-1 positivity 
rate ranged between 2 and 20%. Conversely, VIPomas 
with an MIB-1 proliferative index between 2 and 20% ex-
pressed both sst2 and GIP receptors at high levels. A sin-
gle VIPoma with MIB-1 >20% exhibited a very high sst2, 
but a low GIP receptor density.
 Bronchopulmonary NEN  
 Bronchopulmonary NEN expressed sst2 at lower inci-
dence rates than the majority of gastrointestinal NEN, but 
often in high densities. Conversely, they expressed GIP re-
ceptors at high incidence rates, but in more variable densi-
ties. In fact, GIP receptor density levels progressively de-
clined with increasing MIB-1 positivity, which was statisti-
cally significant for the cases with MIB-1 >2.5% (r 2 = 
0.2656; p = 0.007). In bronchial NEN with MIB-1  ≥ 8%, 
GIP receptor density levels were always moderate or low. 
 Tumor Stage and Somatostatin and GIP Receptor 
Expression in NEN  
 In 75 of the 114 NEN (66%), data on TNM stage were 
available. For further analysis, these cases were subdivid-
ed into two biologically and clinically distinct groups, 
namely those without evidence of metastasis (N0 M0) 
and those with nodal and/or distant metastases (N+/M+). 
Results are summarized in  table 1 . 
 In gastrointestinal NEN, the incidences of both sst2 
and GIP receptors were generally high in metastasized 
cases, except for glucagonomas, where the sst2 incidence 
amounted to only 50%. When comparing N+/M+ tumors 
with N0 M0 tumors, receptor incidences were either 
equally high or higher, but never lower in the former. This 
was particularly the case for the sst2 incidences in non-
functioning pancreatic NEN and insulinomas, which were 
prominently higher in the metastasized cases. Likewise, 
mean receptor density levels were almost always similarly 
high or higher in N+/M+ compared with N0 M0 tumors, 
the only exception being gastrinomas where GIP receptor 
densities were slightly reduced in metastasized cases. 
125I-[Tyr3]-octreotide binding density
Insulinoma
Gastrinoma
Lung NET
HE
Total Total NonspecificNonspecific
125I-GIP(1–30) binding density
a b c d e
f g h i k
l m n o p
 Fig. 4. Comparison of  125 I-[Tyr3]-octreotide with  125 I-GIP(1–30) 
autoradiography on serial tissue sections of an insulinoma (first 
row), a gastrinoma (middle row), and a bronchial NEN (last row). 
Column 1: HE-stained tissue sections (bars = 1 mm). Columns 2 
and 3:  125 I-[Tyr3]-octreotide autoradiography, where column 2 
shows total  125 I-[Tyr3]-octreotide binding and column 3 nonspe-
cific  125 I-[Tyr3]-octreotide binding in the presence of excess cold 
octreotide. Columns 4 and 5:  125 I-GIP(1–30) autoradiography, 
where column 4 shows total  125 I-GIP(1–30) binding and column 5 
nonspecific  125 I-GIP(1–30) binding in the presence of excess cold 
GIP(1–30).  a–e Example of an insulinoma with a high sst2 but low 
GIP receptor expression: the tumor ( a ) exhibits strong  125 I-[Tyr3]-
octreotide binding ( b ,  c ) but only little specific  125 I-GIP(1–30) 
binding ( d ,  e ).  f–k Example of a gastrinoma with a high expres-
sion of both sst2 and GIP receptors: the tumor ( f ) shows strong 
specific binding of both  125 I-[Tyr3]-octreotide ( g ,  h ) and  125 I-
GIP(1–30) ( i ,  k ).  l–p Example of a bronchial NEN with a high GIP 
receptor expression but no sst2 expression. In the tumor ( l ), there 
is no detectable  125 I-[Tyr3]-octreotide binding ( m ,  n ) but strong 
 125 I-GIP(1–30) binding ( o ,  p ). NET = Neuroendocrine tumor. 
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 In bronchial NEN, sst2 incidence was moderate in N0 
M0 tumors and higher in N+/M+ cases, while the sst2 
density levels were high in both tumor groups. In con-
trast, GIP receptor density levels were fairly high in non-
metastasized cases, but showed a reduction in N+/M+ tu-
mors. 
 However, differences in receptor incidences and den-
sity levels between N0/M0 and N+/M+ tumors did not 
reach statistical significance in any investigated tumor 
subgroup.
 Comparison of sst2 and GIP Receptor Levels in NEN  
 The binding site density levels of sst2 and GIP recep-
tors were also compared with each other in the individu-
al tumors. The data are shown in  figure 3 and are illus-
trated with typical examples in  figure 4 . 
 In ileal NEN, the majority of the cases expressed sst2 
and GIP receptors at comparable levels: both receptors 
were present in similarly high or low density or were com-
pletely negative in the same tumor specimen. In only 2 
tumors (marked in red in  fig. 3 ) were sst2 levels mark-
edly higher than GIP receptor levels, while 3 cases (marked 
in blue in  fig. 3 ) showed a considerably stronger GIP re-
ceptor than sst2 expression. 
 Likewise, in nonfunctioning pancreatic NEN, most 
cases expressed both sst2 and GIP receptors at high levels. 
Only 2 tumors showed a considerably stronger GIP re-
ceptor than sst2 expression, and the reverse was seen in a 
third tumor. 
 Conversely, in insulinomas, the sst2 and GIP receptor 
expressions were often not congruent. Many of the cases 
with high sst2 density levels expressed low amounts of 
GIP receptors (red in  fig. 3 ). This is also illustrated with a 
typical example in  figure 4 (first row). On the other hand, 
many tumors virtually negative for sst2 showed moderate 
or high GIP receptor density levels (blue in  fig. 3 ). 
 Most gastrinomas, glucagonomas, and VIPomas ex-
pressed sst2 and GIP receptors in comparable density. 
One of these cases, a gastrinoma, is depicted in  figure 4 
(middle row). Only single cases (one glucagonoma and 
one gastrinoma) showed high GIP receptor levels in the 
absence of sst2 expression.
 Of the investigated bronchopulmonary NEN, 5 cases 
with only low or no GIP receptor expression showed high 
to very high sst2 levels. Conversely, most cases complete-
ly negative for sst2 expressed GIP receptors in low to 
moderate density. One such case is shown in  figure 4 (last 
row). 
 Discussion  
 In the classification of gastrointestinal NEN, empha-
sis has been put on a simple and uniform grading and 
staging system in recent times as the basis for prognos-
tication, standardized therapy, and clinical studies. In-
deed, tumor grade and stage correlate very well with bi-
ologic behavior. At the same time, it becomes apparent 
that peptide hormone receptors like somatostatin recep-
tors, crucial molecular targets in NEN, exhibit a differ-
ential expression in these tumors which does not uni-
formly match with grade, stage, or the proliferative in-
dex. In the present study, this was for the first time 
systematically analyzed for sst2 and GIP receptors in a 
large selection of gastrointestinal and bronchopulmo-
nary NEN. In summary, a number of possible peptide 
receptor expression patterns were identified in various 
NEN subgroups. These patterns differed depending on 
tumor type and site of tumor origin and also correlated 
partially with the MIB-1 index. Such sst2 and GIP recep-
tor expression patterns are only emerging and will even-
tually have to be confirmed in a larger number of tu-
mors. 
 First of all, the case collection reflects known typical 
features of peptide receptor expressions in NEN  [14, 17] . 
Both sst2 and GIP receptors showed high incidences and 
densities (i.e. >3,000 dpm/mg) in gastrointestinal NEN, 
but lower expression levels in bronchopulmonary NEN. 
Furthermore, sst2 generally exhibited higher density lev-
els than GIP receptors, while GIP receptors were ex-
pressed at higher incidence rates. Finally, the expression 
of both receptors was generally reduced in NEN with an 
MIB-1 proliferative index above 20% compared with tu-
mors with lower proliferation. In grade 3 NEN, GIP re-
ceptors mostly showed no or low expression levels (den-
sity levels <1,000 dpm/mg), whereas the sst2 expression 
was more often high. 
 Beyond that, peptide receptor levels were for the first 
time found to either increase or diminish progressively 
with growing proliferative rates. This was usually appar-
ent in only a part of the proliferative spectrum and was 
frequently found for GIP receptors, while sst2 was more 
often expressed at random. Specifically, significant in-
creases or trends for increases in GIP receptor levels with 
higher proliferative indices were present in grade 1 and 2 
nonfunctioning pancreatic NEN and in insulinomas with 
MIB-1 positivity between 2 and 5%. Conversely, a pro-
gressive decrease in the GIP receptor expression with 
higher proliferation was observed in ileal and broncho-
pulmonary NEN. In contrast, for sst2, only an insignifi-
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cant trend for increased levels with higher MIB-1 expres-
sion was found in grade 1 and 2 nonfunctioning pancre-
atic NEN. 
 Moreover, MIB-1 levels were observed in several NEN 
types above which peptide receptors showed consistently 
high or low densities. Of importance, these MIB-1 levels 
were not equivalent to those which defined tumor grade. 
They were exclusively seen for GIP receptors, but not for 
sst2. Specifically, GIP receptor levels were always high in 
insulinomas with MIB-1  ≥ 5%, but consistently low in il-
eal NEN with MIB-1  ≥ 16% and in bronchial NEN with 
MIB-1  ≥ 8%. While the absolute values of these various 
MIB-1 levels are only observations in one study popula-
tion, they illustrate that tumor grade itself, defined by ar-
bitrary MIB-1 cutoff levels and comprising a large MIB-1 
spectrum, does not match with peptide receptor expres-
sion. 
 In the same context, sst2 expression levels in high-
grade NEN with MIB-1 fractions above 20% are notewor-
thy, even though only a small number of tumors could be 
analyzed due to the rarity of these cases  [19] . In fact, it has 
been generally assumed that grade 3 NEN consistently 
show low somatostatin receptor expression levels. This 
concept has been supported by only little data derived 
mainly from somatostatin receptor imaging studies  [19, 
32] , while it has been rarely investigated at the tissue level. 
The sst2 incidence of 57% collected in vitro in tumor sam-
ples in the present study is well in agreement with pub-
lished somatostatin receptor imaging results. However, 
the present study provides important additional informa-
tion by measuring sst2 density in vitro directly in tumor 
samples. Although sst2 densities were overall lower in 
grade 3 NEN compared with better differentiated tumors, 
they were still high in individual cases, as shown in  table 2 . 
Tumors with such strong receptor expression can be ex-
pected to be well suited for targeted imaging and therapy. 
Of note, the sst2 expression in high-grade NEN was quite 
unpredictable in the present tumor cohort. In particular, 
it was independent of MIB-1 levels, tumoral hormone 
production, or site of tumor origin. It will clearly be worth-
while to analyze a larger number of grade 3 NEN for their 
somatostatin receptor expression at the tissue level. 
 Finally, sst2 and GIP receptor expression patterns were 
found to differentially correlate with tumor stage. sst2 in-
cidences and densities were usually higher or, more rarely, 
similar in NEN with nodal and/or distant metastasis com-
pared with tumors without evidence of metastasis. In con-
trast, GIP receptor levels were lower in metastasized ver-
sus nonmetastasized bronchopulmonary NEN, while they 
showed less difference in gastrointestinal NEN.
 It was also interesting to compare in individual tumors 
the expression of sst2 with that of GIP receptors. Indeed, 
sst2 and GIP receptor levels were either similar or strik-
ingly disparate in a given case. This was rather tumor spe-
cific. In ileal NEN, nonfunctioning pancreatic NEN, and 
functioning pancreatic NEN other than insulinomas, ex-
pression levels of the two receptors were comparable in 
the majority of cases. Conversely, in insulinomas and a 
subset of bronchopulmonary NEN, there were often sub-
stantial differences in sst2 and GIP receptor levels, with a 
high expression of one receptor and a low or no expres-
sion of the other. 
 In conclusion, although the expression of peptide re-
ceptors is a universal and highly typical feature of com-
mon gastrointestinal and bronchopulmonary NEN, it 
seems to differ between various tumor types and also to 
partially correlate with the proliferative index. The GIP 
receptor expression in NEN appears more often to follow 
a rule than the sst2 expression. At present, it can only be 
speculated on its biological significance. GIP receptors 
can stimulate insulin secretion and possibly also tumor 
cell proliferation  [33, 34] . Accordingly, increased GIP re-
ceptor expression in insulinomas with low proliferative 
activity could promote insulin secretion. Likewise, in 
grade 1 and 2 nonfunctioning NEN it may stimulate tu-
mor cell proliferation. On the other hand, a decrease in 
GIP receptor levels in ileal and bronchopulmonary NEN 
with growing proliferative activity may be reflective of tu-
mor dedifferentiation. It appears that if GIP receptors 
play a significant biological role in NEN, this may vary 
between different tumor types. 
 As for clinical applications, the present study confirms 
that common NEN are good candidates for peptide re-
ceptor targeting for imaging and radiotherapeutic pur-
poses based on the generally high peptide receptor inci-
dences and densities (i.e. >3,000 dpm/mg). Of impor-
tance, the data underline that this accounts not only for 
cases with a proliferative index below 20%, but also for a 
substantial subset of grade 3 tumors. Moreover, they 
highlight the potential of multireceptor targeting directed 
simultaneously at both sst2 and GIP receptors as soon as 
GIP receptor targeting is clinically available. An additive 
targeting effect can be expected in ileal and nonfunction-
ing pancreatic NEN, which express both receptors con-
comitantly. Conversely, in insulinomas and bronchopul-
monary NEN, where often only 1 of the 2 receptors is 
present in sufficient amounts, dual receptor targeting 
may be the method of choice, as the tumor would be 
missed by single receptor targeting. 
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 In terms of tumor testing, the study results emphasize 
the need to characterize each individual NEN for its pep-
tide receptor expression when clinical applications are an 
option. The indications for in vitro tumor testing have 
been summarized previously  [35] . At present, widespread 
in vitro testing is possible for sst2 since a good immuno-
histochemical antibody is commercially available  [24] . 
Indeed, in vitro testing of sst2 in NEN is reasonable due 
to the unpredictable variations in the sst2 expression. In 
particular, high-grade NEN need to be tested in order to 
identify those cases with strong sst2 expression. We be-
lieve that in the era of personalized, targeted medicine, it 
is essential to gather as much information as possible on 
an individual tumor to be able to interdisciplinarily de-
fine the best ways of management and follow-up, espe-
cially if an inexpensive test such as sst2 immunohisto-
chemistry is available and alternative powerful therapeu-
tic options are scarce.
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